# A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

> **NCT02292706** · — · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 1609 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** Ribavirin
- **DRUG:** LDV/SOF
- **DRUG:** SOF/VEL
- **DRUG:** SOF/VEL/VOX
- **DRUG:** Other SOF-Based Regimen
- **OTHER:** Ineligible parent treatment

## Key facts

- **NCT ID:** NCT02292706
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12-29
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 1609 (ACTUAL)
- **Why stopped:** The study stopped early because the study objectives were met.
- **Last updated:** 2023-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02292706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02292706, "A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02292706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*